ALKS
Alkermes Plc
NASDAQ: ALKS · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$33.71
-1.26% today
Updated 2026-04-29
Market cap
$5.62B
P/E ratio
23.57
P/S ratio
3.81x
EPS (TTM)
$1.43
Dividend yield
—
52W range
$25 – $36
Volume
2.4M
Alkermes Plc (ALKS) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$33.71
12-Month target
$28.21
2030 Target
—
Intrinsic (DCF)
$76.10
Financial forecast
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $1.2B | $1.1B | $1.7B | $1.6B | $1.5B |
| EPS | — | — | — | — | — |
CAGR applied: — (capped 20%) · P/E: 23.57x (capped 25x) · Margin: 16.40%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.